Cytokinetics (CYTK) EBIAT (2016 - 2024)
Historic EBIAT for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to -$150.0 million.
- Cytokinetics' EBIAT fell 958.68% to -$150.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$589.5 million, marking a year-over-year decrease of 1202.52%. This contributed to the annual value of -$589.5 million for FY2024, which is 1202.52% down from last year.
- Per Cytokinetics' latest filing, its EBIAT stood at -$150.0 million for Q4 2024, which was down 958.68% from -$160.5 million recorded in Q3 2024.
- Cytokinetics' EBIAT's 5-year high stood at -$3.2 million during Q3 2020, with a 5-year trough of -$160.5 million in Q3 2024.
- In the last 5 years, Cytokinetics' EBIAT had a median value of -$109.0 million in 2022 and averaged -$92.4 million.
- Per our database at Business Quant, Cytokinetics' EBIAT surged by 8926.39% in 2020 and then plummeted by 229640.94% in 2021.
- Quarter analysis of 5 years shows Cytokinetics' EBIAT stood at -$43.9 million in 2020, then skyrocketed by 30.41% to -$30.6 million in 2021, then crashed by 349.39% to -$137.4 million in 2022, then increased by 0.35% to -$136.9 million in 2023, then fell by 9.59% to -$150.0 million in 2024.
- Its EBIAT was -$150.0 million in Q4 2024, compared to -$160.5 million in Q3 2024 and -$143.3 million in Q2 2024.